Motoi Kanagawa Selected Research

Walker-Warburg Syndrome

1/2018	Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.
1/2016	Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.
2/2015	Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
1/2014	Contribution of dysferlin deficiency to skeletal muscle pathology in asymptomatic and severe dystroglycanopathy models: generation of a new model for Fukuyama congenital muscular dystrophy.
10/2013	GTDC2 modifies O-mannosylated α-dystroglycan in the endoplasmic reticulum to generate N-acetyl glucosamine epitopes reactive with CTD110.6 antibody.
4/2013	[Fukuyama muscular dystrophy: elucidation of the gene and pathogenesis and approaches toward molecular targeting therapy].
10/2011	Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy.
12/2006	Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Motoi Kanagawa Research Topics

Disease

26	Muscular Dystrophies (Muscular Dystrophy) 01/2022 - 07/2002
8	Walker-Warburg Syndrome 01/2018 - 12/2006
3	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 08/2011 - 02/2009
2	Muscular Diseases (Myopathy) 01/2022 - 01/2019
2	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2018 - 11/2013
2	Parkinson Disease (Parkinson's Disease) 11/2018 - 11/2013
1	Myositis (Idiopathic Inflammatory Myopathies) 01/2022
1	Inclusion Body Myositis 01/2022
1	Polymyositis 01/2022
1	Antisynthetase syndrome 01/2022
1	Cardiomyopathies (Cardiomyopathy) 01/2022
1	Heterotopic Ossification (Ectopic Ossification) 01/2021
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Dementia (Dementias) 01/2020
1	Neuromuscular Diseases (Neuromuscular Disease) 01/2019
1	Multiple System Atrophy 01/2019
1	Diabetes Mellitus 11/2018
1	Hypertension (High Blood Pressure) 11/2018
1	Melanoma (Melanoma, Malignant) 11/2018
1	Malformations of Cortical Development 01/2018
1	Lissencephaly 03/2016
1	Arenaviridae Infections 10/2011
1	Hypercholesterolemia 10/2011
1	Type 1C Limb-Girdle Muscular Dystrophy 08/2011
1	Cognitive Dysfunction 03/2011
1	Eye Abnormalities (Eye Abnormality) 10/2010
1	Pheochromocytoma 06/2007
1	Lassa Fever (Fever, Lassa) 11/2005
1	Carcinoma (Carcinomatosis) 09/2004

Drug/Important Bio-Agent (IBA)

23	Dystroglycans (Dystroglycan)IBA 01/2022 - 07/2002
7	Laminin (Merosin)IBA 01/2018 - 07/2004
6	RibitolIBA 01/2022 - 03/2016
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 11/2005
6	Polysaccharides (Glycans)IBA 01/2020 - 07/2004
5	Phosphates (Orthophosphate)IBA 01/2022 - 03/2016
4	GlycosyltransferasesIBA 01/2016 - 07/2004
4	LigandsIBA 03/2012 - 07/2002
2	EnzymesIBA 01/2022 - 01/2006
2	TransferasesIBA 01/2020 - 01/2018
2	Mannose (D-Mannose)IBA 01/2016 - 10/2010
2	protein O-mannose beta-1,2-N-acetylglucosaminyltransferaseIBA 01/2016 - 10/2010
1	ProdrugsIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	cytidine diphosphate ribitolIBA 01/2022
1	Cadherins (E-Cadherin)IBA 01/2022
1	Cell Adhesion MoleculesIBA 01/2022
1	Terpenes (Terpenoids)IBA 01/2022
1	lubricinIBA 01/2021
1	Peptides (Polypeptides)IBA 01/2020
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	alpha-SynucleinIBA 01/2019
1	dabrafenibIBA 11/2018
1	Pharmaceutical PreparationsIBA 11/2018
1	NeurotoxinsIBA 11/2018
1	Proto-Oncogene Proteins B-rafIBA 11/2018
1	PolymersIBA 02/2015
1	Insulin-Like PeptidesIBA 09/2014
1	Insulin-Like Growth Factor I (IGF-1)IBA 09/2014
1	DysferlinIBA 01/2014
1	SynucleinsIBA 11/2013
1	O-GlcNAc transferaseIBA 10/2013
1	Epidermal Growth Factor (EGF)IBA 10/2013
1	Alanine (L-Alanine)FDA Link 10/2013
1	MM Form Creatine KinaseIBA 08/2013
1	TB-403IBA 10/2011
1	LipidsIBA 10/2011
1	Retroelements (Retrotransposon)IBA 10/2011
1	Caveolin 3IBA 08/2011
1	Retinaldehyde (Retinal)IBA 08/2008
1	Acetylcholine (Acetylcholine Chloride)FDA Link 06/2007
1	DystrophinIBA 01/2006
1	CollagenIBA 01/2006
1	Glycoproteins (Glycoprotein)IBA 01/2006
1	Cell Surface ReceptorsIBA 11/2005
1	Peptide Hydrolases (Proteases)FDA Link 09/2004

Therapy/Procedure

3	Therapeutics 01/2022 - 04/2013
1	Ligation 01/2019